Prognostic Significance of Extracellular Matrix Degrading Enzymes—Cathepsin L and Matrix Metalloproteases-2 [MMP-2] in Human Pancreatic Cancer

REFERENCES

• DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464–1484.
   PubMed Web of Science ®Google Scholar
• Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005;128:1626–1641.
   PubMed Web of Science ®Google Scholar
• Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721–731; discussion 731–723.
   PubMed Web of Science ®Google Scholar
• Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375–379.
   PubMed Web of Science ®Google Scholar
• De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429–447.
   PubMed Web of Science ®Google Scholar
• Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918–926.
   PubMed Web of Science ®Google Scholar
• Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, Streit S, Michalski CW, Friess H, Kleeff J. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2008;7:1352–1359.
   PubMed Web of Science ®Google Scholar
• Sato N, Maehara N, Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 2004;64:6950–6956.
   PubMed Web of Science ®Google Scholar
• Denhardt DT, Greenberg AH, Egan SE, Hamilton RT, Wright JA. Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene 1987;2:55–59.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 (Suppl):S42–S51.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Gunzler WA, Janicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 1991;266:5147–5152.
   PubMed Web of Science ®Google Scholar
• Lah TT, Kokalj-Kunovar M, Strukelj B, Pungercar J, Barlic-Maganja D, Drobnic-Kosorok M, Kastelic L, Babnik J, Golouh R, Turk V. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 1992;50:36–44.
   PubMed Web of Science ®Google Scholar
• Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1990;1:137–152.
   PubMedGoogle Scholar
• Collette J, Bocock JP, Ahn K, Chapman RL, Godbold G, Yeyeodu S, Erickson AH. Biosynthesis and alternate targeting of the lysosomal cysteine protease cathepsin L. Int Rev Cytol 2004;241:1–51.
   PubMed Web of Science ®Google Scholar
• Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005;52:1–9.
   PubMedGoogle Scholar
• Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G, Van Noorden CJ. Cathepsin L, target in cancer treatment? Life Sci 2010;86:225–233.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Iwadate M, Yanagisawa Y, Ito E, Imai J, Yamamoto M, Sawada N, Saito M, Suzuki S, Nakamura I, Ohki S, Saze Z, Kogure M, Gotoh M, Omicronbara K, Ohira H, Tasaki K, Abe M, Goshima N, Watanabe S, Waguri S, Takenoshita S. Cathepsin L is highly expressed in gastrointestinal stromal tumors. Int J Oncol 2011;39:1109–1115.
   PubMed Web of Science ®Google Scholar
• Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Janicke F, Graeff H. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res 1995;1:741–746.
   PubMed Web of Science ®Google Scholar
• Yan JA, Xiao H, Ji HX, Shen WH, Zhou ZS, Song B, Chen ZW, Li WB. Cathepsin L is associated with proliferation and clinical outcome of urothelial carcinoma of the bladder. J Int Med Res 2010;38:1913–1922.
   PubMed Web of Science ®Google Scholar
• Niedergethmann M, Wostbrock B, Sturm JW, Willeke F, Post S, Hildenbrand R. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004;29:204–211.
   PubMed Web of Science ®Google Scholar
• Birkedal-Hansen H. Proteolytic remodelling of extracellular matrix. Curr Opin Cell Biol 1995;7:728–735.
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y, Hasegawa S, Wada H, Tanaka F. Matrix metallo- proteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004;10:6579–6585.
   PubMed Web of Science ®Google Scholar
• Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA, Jr., Kallakury BV. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003;16:198–205.
   PubMed Web of Science ®Google Scholar
• Sivula A, Talvensaari-Mattila, A., Lundin, J., Joensuu, H., Haglund, C., Ristimaki, A., Turpeenniemi-Hujanen, T. Association of cyclo-oxygenase-2 and matrix metaloproteinase -2 expression in human breast cancer. Breast cancer res treat 2005;89:215–220.
   PubMed Web of Science ®Google Scholar
• Torng PL, Mao TL, Chan WY, Huang SC, Lin, CT. Prognostic significance of stromal metalloproteinase - 2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 2004;92:559–567.
   PubMed Web of Science ®Google Scholar
• Vasala K, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 2003;62:952–957.
   PubMed Web of Science ®Google Scholar
• Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455–465.
   PubMed Web of Science ®Google Scholar
• Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003;2:14.
   PubMedGoogle Scholar
• Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res 1991;51:1478–1481.
   PubMed Web of Science ®Google Scholar
• Mason RW, Johnson DA, Barrett AJ, Chapman HA. Elastinolytic activity of human cathepsin L. Biochem J 1986;233:925–927.
   PubMed Web of Science ®Google Scholar
• Ohtani H. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int 1998;48:1–9.
   PubMed Web of Science ®Google Scholar
• Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997;91:439–442.
   PubMed Web of Science ®Google Scholar
• Liotta LA. Tumor invasion and metastases–role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1–7.
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347–355.
   PubMed Web of Science ®Google Scholar
• Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764–775.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Kondo C, Kojima T, Nagata H, Moriyama A, Hayakawa T, Katunuma N. Significance of 32-kDa cathepsin L secreted from cancer cells. Cancer Biother Radiopharm 2006;21:217–224.
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006;66: 6699–6707.
   PubMed Web of Science ®Google Scholar
• Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000;28:31–39.
   PubMedGoogle Scholar
• Xu X, Yuan G, Liu W, Zhang Y, Chen W. Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance. Exp Oncol 2009;31:102–105.
   PubMedGoogle Scholar
• Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998;16:1013–1021.
   PubMed Web of Science ®Google Scholar
• Juuti A, Lundin J, Nordling S, Louhimo J, Haglund C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2006;71:61–68.
   PubMed Web of Science ®Google Scholar
• Yeghiazaryan M, Zybura-Broda K, Cabaj A, Wlodarczyk J, Slawinska U, Rylski M, Wilczynski GM. Fine-structural distribution of MMP-2 and MMP-9 activities in the rat skeletal muscle upon training: a study by high-resolution in situ zymography. Histochem Cell Biol 2012;138:75–87.
   PubMed Web of Science ®Google Scholar
• Hill JW, Poddar R, Thompson JF, Rosenberg GA, Yang Y. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 2012;220:277–290.
   PubMed Web of Science ®Google Scholar
• Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004;18:690–692.
   PubMed Web of Science ®Google Scholar
• Iki K, Tsutsumi M, Kido A, Sakitani H, Takahama M, Yoshimoto M, Motoyama M, Tatsumi K, Tsunoda T, Konishi Y. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1999;20:1323–1329.
   PubMed Web of Science ®Google Scholar
• Bloomston M, Zervos EE, Rosemurgy AS, 2nd. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002;9:668–674.
   PubMed Web of Science ®Google Scholar
• Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, Doi R, Arii S, Imamura M. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642–650.
   PubMed Web of Science ®Google Scholar
• Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H, Sato M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 1997;70:120–127.
   PubMed Web of Science ®Google Scholar
• Gong YL, Xu GM, Huang WD, Chen LB. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol 2000;73:95–99.
   PubMed Web of Science ®Google Scholar